1431 related articles for article (PubMed ID: 32946820)
1. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial.
Feig DS; Donovan LE; Zinman B; Sanchez JJ; Asztalos E; Ryan EA; Fantus IG; Hutton E; Armson AB; Lipscombe LL; Simmons D; Barrett JFR; Karanicolas PJ; Tobin S; McIntyre HD; Tian SY; Tomlinson G; Murphy KE;
Lancet Diabetes Endocrinol; 2020 Oct; 8(10):834-844. PubMed ID: 32946820
[TBL] [Abstract][Full Text] [Related]
2. Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes.
Dodd JM; Grivell RM; Deussen AR; Hague WM
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD010564. PubMed ID: 30039871
[TBL] [Abstract][Full Text] [Related]
3. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multi-center randomized controlled trial.
Feig DS; Murphy K; Asztalos E; Tomlinson G; Sanchez J; Zinman B; Ohlsson A; Ryan EA; Fantus IG; Armson AB; Lipscombe LL; Barrett JF;
BMC Pregnancy Childbirth; 2016 Jul; 16(1):173. PubMed ID: 27435163
[TBL] [Abstract][Full Text] [Related]
4. Effect of metformin in addition to dietary and lifestyle advice for pregnant women who are overweight or obese: the GRoW randomised, double-blind, placebo-controlled trial.
Dodd JM; Louise J; Deussen AR; Grivell RM; Dekker G; McPhee AJ; Hague W
Lancet Diabetes Endocrinol; 2019 Jan; 7(1):15-24. PubMed ID: 30528218
[TBL] [Abstract][Full Text] [Related]
5. Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Chiswick C; Reynolds RM; Denison F; Drake AJ; Forbes S; Newby DE; Walker BR; Quenby S; Wray S; Weeks A; Lashen H; Rodriguez A; Murray G; Whyte S; Norman JE
Lancet Diabetes Endocrinol; 2015 Oct; 3(10):778-86. PubMed ID: 26165398
[TBL] [Abstract][Full Text] [Related]
6. Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial.
Løvvik TS; Carlsen SM; Salvesen Ø; Steffensen B; Bixo M; Gómez-Real F; Lønnebotn M; Hestvold KV; Zabielska R; Hirschberg AL; Trouva A; Thorarinsdottir S; Hjelle S; Berg AH; Andræ F; Poromaa IS; Mohlin J; Underdal M; Vanky E
Lancet Diabetes Endocrinol; 2019 Apr; 7(4):256-266. PubMed ID: 30792154
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
[TBL] [Abstract][Full Text] [Related]
8. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial.
Feig DS; Donovan LE; Corcoy R; Murphy KE; Amiel SA; Hunt KF; Asztalos E; Barrett JFR; Sanchez JJ; de Leiva A; Hod M; Jovanovic L; Keely E; McManus R; Hutton EK; Meek CL; Stewart ZA; Wysocki T; O'Brien R; Ruedy K; Kollman C; Tomlinson G; Murphy HR;
Lancet; 2017 Nov; 390(10110):2347-2359. PubMed ID: 28923465
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
[TBL] [Abstract][Full Text] [Related]
10. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
[TBL] [Abstract][Full Text] [Related]
11. Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial.
Feig DS; Sanchez JJ; Murphy KE; Asztalos E; Zinman B; Simmons D; Haqq AM; Fantus IG; Lipscombe L; Armson A; Barrett J; Donovan L; Karanicolas P; Tobin S; Mangoff K; Klein G; Jiang Y; Tomlinson G; Hamilton J;
Lancet Diabetes Endocrinol; 2023 Mar; 11(3):191-202. PubMed ID: 36746160
[TBL] [Abstract][Full Text] [Related]
12. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial.
Halberg IB; Lyby K; Wassermann K; Heise T; Zijlstra E; Plum-Mörschel L
Lancet Diabetes Endocrinol; 2019 Mar; 7(3):179-188. PubMed ID: 30679095
[TBL] [Abstract][Full Text] [Related]
14. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes.
Farrar D; Tuffnell DJ; West J; West HM
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD005542. PubMed ID: 27272351
[TBL] [Abstract][Full Text] [Related]
15. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Rosenstock J; Frias J; Jastreboff AM; Du Y; Lou J; Gurbuz S; Thomas MK; Hartman ML; Haupt A; Milicevic Z; Coskun T
Lancet; 2023 Aug; 402(10401):529-544. PubMed ID: 37385280
[TBL] [Abstract][Full Text] [Related]
16. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.
Ludvik B; Frías JP; Tinahones FJ; Wainstein J; Jiang H; Robertson KE; García-Pérez LE; Woodward DB; Milicevic Z
Lancet Diabetes Endocrinol; 2018 May; 6(5):370-381. PubMed ID: 29483060
[TBL] [Abstract][Full Text] [Related]
17. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á
Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970
[TBL] [Abstract][Full Text] [Related]
18. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
[TBL] [Abstract][Full Text] [Related]
19. Metformin Plus Insulin for Preexisting Diabetes or Gestational Diabetes in Early Pregnancy: The MOMPOD Randomized Clinical Trial.
Boggess KA; Valint A; Refuerzo JS; Zork N; Battarbee AN; Eichelberger K; Ramos GA; Olson G; Durnwald C; Landon MB; Aagaard KM; Wallace K; Scifres C; Rosen T; Mulla W; Valent A; Longo S; Young L; Marquis MA; Thomas S; Britt A; Berry D
JAMA; 2023 Dec; 330(22):2182-2190. PubMed ID: 38085312
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
